- Mahlich, J., Bartol, A., Dheban, S. (2021), Can Adaptive Clinical Trials Help to Solve the Productivity Crisis of the Pharmaceutical Industry? - a Scenario Analysis, Health Economics Review 11(4).
- Mahlich, J., May, M., Feig, C., Straub, V., Schmelz, R. (2021), Persistence with Biologic Therapy and Associated Costs of Patients with Inflammatory Bowel Disease: A German Retrospective Claims Data Analysis, Crohn’s & Colitis 360 3(2).
- Mahlich, J., Olbrich, K., Wilk, A., Wimmer, A., Wolff-Menzler, C. (2020), Hospitalization Rates and Therapy Costs of German Schizophrenia Patients who are Initiated on Long-Acting Injectable Medication: A Mirror Image Study, Clinical Drug Investigation 40: 355–375.
- Mahlich, J., Yurtoglu, B. (2019), Returns on Different Types of Investment in the Global Pharmaceutical Industry, Managerial and Decision Economics 40(1): 16-36.
- Mahlich, J., Sindern, J., Suppliet, M. (2019), Cross-National Drug Price Comparisons with Economic Weights in External Reference Pricing in Germany, Expert Review of Pharmacoeconomics & Outcomes Research 19(1): 37-43.
- Mahlich, J., Sruamsiri, R. (2019), Co-Insurance and Health Care Utilization in Japanese Patients with Rheumatoid Arthritis: a Discontinuity Regression Approach, International Journal for Equity in Health 18.
- Mahlich, J., Alba, A., El Hadad, L., Leisten, M.-K., Peitsch, W. (2019), Drug survival of biological therapies for psoriasis treatment in Germany and associated costs: a retrospective claims database analysis, Advances in Therapy 36(7): 1684–1699.
- Mahlich, J., Schaede, U., Sruamsiri, R. (2019), Shared Decision-Making and Patient Satisfaction in Japanese Rheumatoid Arthritis Patients: A New “Preference Fit” Framework for Treatment Assessment, Rheumatology and Therapy 6(2): 269-283.
- Mahlich, J., Dilokthornsakul, P., Sruamsiri, R., Chaiyakunapruk, N. (2018), Cultural beliefs, utility values, and health technology assessment, Cost Effectiveness and Resource Allocation 16, 19.
|
